Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF
Date of Report (date of earliest event reported): January 25, 2013
(Exact name of Registrant as Specified in its Charter)
(State Or Other Jurisdiction Of Incorporation)
Registrant’s Telephone Number, Including Area Code
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Items under Sections 1 through 4 and 6 through 8 are not applicable and therefore omitted.
On January 25, 2013, the Board of Directors of Urologix, Inc. (the “Company”) appointed Gregory J. Fluet as the Company’s Chief Executive Officer and elected him as a director to serve until the Annual Meeting of Shareholders following the Company’s fiscal year 2015 or until his successor is elected and shall qualify. The Governance/Nominating Committee of the Board of Directors of the Company recommended Mr. Fluet be appointed as the Company’s Chief Executive Officer on a non-interim basis and recommended that Mr. Fluet be elected to the Board. Mr. Fluet had been serving as the Company’s Interim Chief Executive Officer since November 30, 2012 and previously served as the Company’s Executive Vice President and Chief Operating Officer from July 2008 to November 30, 2012.
On January 30, 2013, the Company issued a press release relating to the foregoing matters, which press release is attached hereto as Exhibit 99.1.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: January 30, 2013